# Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)

> **NCT04278885** · PHASE2 · UNKNOWN · sponsor: **Charite University, Berlin, Germany** · enrollment: 4 (actual)

## Conditions studied

- Hereditary Autoinflammatory Disease

## Interventions

- **DRUG:** Lanadelumab

## Key facts

- **NCT ID:** NCT04278885
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-05
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04278885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04278885, "Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04278885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*